GB Sciences (GBLX) Stock Price, News & Analysis

Company Overview

GB Sciences, Inc. is a biotechnology company focused on the research, development and commercialization of cannabinoid-based medicines. Leveraging both botanical and synthetic approaches, the company aims to create novel therapies targeting oncology, neurology and inflammatory diseases. Through its proprietary drug discovery platform, GB Sciences seeks to identify and advance lead compounds that harness the therapeutic potential of cannabinoids while ensuring high standards of quality and safety.

The company operates a cGMP-compliant research and manufacturing facility in Irvine, California, and maintains partnerships to support cultivation and extraction activities in select geographies. GB Sciences has secured licenses for cannabis cultivation and product manufacturing in Panama, positioning the company to serve markets across North and Central America. Its product pipeline includes preclinical and early-stage clinical candidates, as well as formulations designed for future human trials in key therapeutic areas.

GB Sciences’ leadership team combines expertise in pharmaceutical development, botanical extraction and regulatory compliance. The company is led by President and Chief Executive Officer Dr. Federico Narváez, MD, whose background spans clinical research and drug development. Supported by scientific and operational executives, GB Sciences continues to pursue strategic collaborations and patent-protected innovations aimed at translating cannabinoid science into meaningful medical treatments.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0059
• Volume: 15,005 shs
• Average Volume: 36,193 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GB Sciences Stock Analysis - MarketRank™

GB Sciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for GB Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of GB Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GB Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

GB Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GB Sciences has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GB Sciences does not currently pay a dividend.

Dividend Growth

GB Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added GB Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GB Sciences insiders have not sold or bought any company stock.

Percentage Held by Institutions

13.56% of the stock of GB Sciences is held by institutions.

Company Calendar

• Last Earnings: 11/14/2016
• Today: 8/06/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GBLX
• CIK: 1165320
• Web: gbsciences.com
• Phone: (866) 721-0297
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A